# Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)

> **NCT02174159** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 18 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Ulonivirine

## Key facts

- **NCT ID:** NCT02174159
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-15
- **Primary completion:** 2015-07-16
- **Final completion:** 2015-07-23
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02174159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02174159, "Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Ulonivirine (MK-8507) in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02174159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*